Study of short bowel syndrome in children
Part of Digestive system clinical trials.
This study looks at short bowel syndrome in children who have had intestinal surgery. It may help doctors understand how to better treat this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child's parent or guardian must agree to join the study (sign a consent form).
- The patient must be between 4 months and 18 years old.
- The patient must have short bowel syndrome or have had surgery to remove part of the intestine.
- You cannot have used the drug teduglutide before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the medicine teduglutide in children (ages 1–17) with Short Bowel Syndrome who need IV nutrition. The goal is to see if teduglutide can help them reduce or stop IV nutrition.
This study looks at how bacteria in your gut help your digestive system adapt after short bowel surgery. Researchers will track your microbiota (the trillions of bacteria in your gut) to understand how it changes and helps your body adjust to having less small intestine.
This study tests a new medicine called apraglutide, given as a shot, to see if it can help adults with short bowel syndrome and intestinal failure reduce their need for intravenous nutrition (parenteral support). The study compares apraglutide to a placebo (a shot with no medicine) to check if it is safe and effective.
This study uses a survey to check how much people and doctors know about using GATTEX. It may help improve education and support for safer, more informed use of the medicine.
This study tests a medicine called teduglutide for adults in China with short bowel syndrome who need long-term IV nutrition or fluids (parenteral support). The goal is to see if teduglutide can help them reduce or stop the need for these IV treatments.
This trial tests a new medication called glepaglutide to see if it can help people with short bowel syndrome (SBS) who need IV nutrition or fluids at least 3 days a week. The goal is to reduce or even stop the need for these IV treatments.
Hear when a new Short Bowel Syndrome (SBS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.